Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 10/20 | 0.38 |
| ▸ | ATR | Q13535 | 9/20 | 0.38 |
| ▸ | ATRIP | Q8WXE1 | 9/20 | 0.38 |
| ▸ | ATM | Q13315 | 5/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.36 |
| ▸ | MELK | Q14680 | 10/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.35 |
| ▸ | SERPINA2 | P20848 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27133782 | 1.00 | PRKDC (0.38) | PRKDCATRATRIPATMPIK3CB | |
| SCHEMBL27129257 | 0.92 | ATR (0.37) | PRKDCATRATRIPATMPIK3CB | |
| SCHEMBL21541718 | 0.92 | ATR (0.37) | PRKDCATRATRIPATMPIK3CB | |
| SCHEMBL21541791 | 0.90 | ATR (0.39) | PRKDCATRATRIPATMPIK3CB | |
| SCHEMBL27124103 | 0.90 | ATR (0.39) | PRKDCATRATRIPATMPIK3CB | |
| SCHEMBL21541720 | 0.88 | ATR (0.40) | PRKDCATRATRIPATMPIK3CB | |
| SCHEMBL21541723 | 0.87 | MELK (0.35) | MELK | |
| SCHEMBL21541861 | 0.84 | PRKDC (0.44) | PRKDCATRATRIPATMPIK3CB | |
| SCHEMBL21541741 | 0.83 | ATR (0.38) | PRKDCATRATRIPATMPIK3CB | |
| SCHEMBL27127196 | 0.83 | ATR (0.38) | PRKDCATRATRIPATMPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567041-B1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2023-12-27 | — | — | EP | claimed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | claimed |
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-12-29 | — | — | US | claimed |
| EP-3567041-A1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics, Inc (CN) | 2019-11-13 | — | — | EP | claimed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3567041-A1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics, Inc (CN) | 2019-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | CHEK1, CHEK2, CDK1 | PRKDC 61/4885ATR 91/4885ATRIP 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.